Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

OTHER 2 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Hepatocellular 5 Leukemia, Myeloid, Acute 3 Uveal Melanoma 2 Stomach Neoplasms 1 Sarcoma 1 Prostatic Neoplasms 1 Ovarian Neoplasms 1 Neoplasms 1 Mesothelioma, Malignant 1 Mesothelioma 1 Melanoma 1 Lymphoma, Non-Hodgkin 1 Liver Neoplasms 1 Leiomyosarcoma 1 HER2 Negative Metastatic Breast Cancer 1 Glioma 1 Glioblastoma 1 Colorectal Neoplasms 1 Carcinoma 1 Advanced Solid Cancers 1 Advanced Pancreatic Cancer 1

Interventions

Temozolomide 94 Radiotherapy 40 Bevacizumab 40 Lomustine 21 Radiation 18 Surgical Procedures, Operative 10 Carboplatin 9 pembrolizumab 8 Nivolumab 8 Carmustine 8 Irinotecan 7 IL13-PE38 6 Granulocyte-Macrophage Colony-Stimulating Factor 6 Flucytosine 6 Cyclophosphamide 6 ABT-414 6 vocimagene amiretrorepvec 5 depatuxizumab mafodotin 5 Valacyclovir 5 Drug Therapy 5 veledimex 4 sargramostim 4 enzastaurin 4 NVP-BKM120 4 Gemcitabine 4 Dianhydrogalactitol 4 Chlorotoxin 4 Aminolevulinic Acid 4 verubulin 3 selinexor 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Glioblastoma × ADI PEG20 × Clear all

NCT04587830 2025-08-26

GBM

Polaris Group

Phase 2 Active not recruiting

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡